Hepatitis B ribozyme gene therapy - Immusol
Latest Information Update: 03 Sep 2002
At a glance
- Originator Immusol
- Class Antivirals; Gene therapies; Ribozyme genes
- Mechanism of Action Ribonuclease stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 03 Sep 2002 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
- 18 Feb 1999 New profile
- 18 Feb 1999 Preclinical development for Hepatitis B in USA (Unknown route)